公开(公告)号：US10301292B2

公开(公告)日：2019-05-28

申请号：US15529816

申请日：2015-11-25

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Ryo Mizojiri ,  Hiroshi Banno ,  Moriteru Asano ,  Daisuke Tomita ,  Noriyuki Nii ,  Hironobu Maezaki ,  Michiko Tawada

IPC: C07D413/04 ,  C07D413/14 ,  A61K31/343 ,  A61K31/381 ,  A61K31/416 ,  A61K31/423 ,  A61K31/428 ,  A61K31/437 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/501 ,  A61K31/517 ,  A61K31/5377 ,  C07D231/56 ,  C07D333/56 ,  C07D401/04 ,  C07D403/04 ,  C07D405/04 ,  C07D413/12 ,  C07D417/04 ,  C07D471/04 ,  C07D263/54 ,  C07D498/04 ,  C07D307/81 ,  C07D263/57 ,  C12N15/09

Abstract: Provided is a bicyclic compound having an acetyl-CoA carboxylase inhibitory action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an acetyl-CoA carboxylase inhibitory action, is useful for the prophylaxis or treatment of cancer, inflammatory diseases and the like, and has superior efficacy.

公开(公告)号：US11584737B2

公开(公告)日：2023-02-21

申请号：US17042394

申请日：2019-03-28

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Koji Ono ,  Masahiro Ito ,  Toshio Tanaka ,  Moriteru Asano ,  Takaharu Hirayama ,  Jun Fujimoto ,  Nobuki Sakauchi ,  Yasuhiro Hirata ,  Akinori Toita ,  Nao Morishita ,  Hironori Kokubo ,  Yasuhiro Imaeda ,  Hironobu Maezaki ,  Douglas Robert Cary ,  Ryo Mizojiri ,  Nobuo Cho ,  Hiroshi Banno ,  Hidekazu Tokuhara ,  Yasuyoshi Arikawa

IPC: C07D401/14 ,  C07D403/14 ,  A61P35/00 ,  C07D213/84 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D471/10 ,  C07D487/10 ,  C07D495/10

Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US11230545B2

公开(公告)日：2022-01-25

申请号：US17367171

申请日：2021-07-02

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takaharu Hirayama ,  Yoshiteru Ito ,  Hiroshi Banno ,  Hidekazu Tokuhara ,  Toshio Tanaka ,  Yasuyoshi Arikawa ,  Noriyuki Nii ,  Youichi Kawakita ,  Shinichi Imamura

IPC: C07D471/04

Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.

公开(公告)号：US11952344B2

公开(公告)日：2024-04-09

申请号：US17754118

申请日：2020-09-25

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yuya Oguro ,  Makoto Kamata ,  Shuhei Ikeda ,  Takeshi Wakabayashi ,  Norihito Tokunaga ,  Taku Kamei ,  Mitsuhiro Ito ,  Shigemitsu Matsumoto ,  Hirotaka Kamitani ,  Takaharu Hirayama ,  Toshio Tanaka ,  Hiroshi Banno ,  Nobuyuki Takakura ,  Jinichi Yonemori ,  Takuya Fujimoto

IPC: C07D213/61 ,  A61K31/444 ,  A61K31/495 ,  A61P25/00 ,  A61P29/00 ,  C07D211/04 ,  C07D213/65 ,  C07D213/68 ,  C07D221/04 ,  C07D237/08 ,  C07D239/26 ,  C07D239/34 ,  C07D333/38 ,  C07D401/12 ,  C07D405/02

CPC classification number: C07D211/04 ,  C07D237/08 ,  C07D239/26 ,  C07D405/02

Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMD A receptor containing the NR2B subunit and that is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I), wherein each symbol is as defined in the DESCRIPTION, or a salt thereof.

公开(公告)号：US10981934B2

公开(公告)日：2021-04-20

申请号：US16663601

申请日：2019-10-25

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Youichi Kawakita ,  Takuto Kojima ,  Noriyuki Nii ,  Yoshiteru Ito ,  Nobuki Sakauchi ,  Hiroshi Banno ,  Xin Liu ,  Koji Ono ,  Keisuke Imamura ,  Shinichi Imamura

IPC: A61K31/53 ,  C07D519/00 ,  A61K31/444 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/4985 ,  A61P35/00

Abstract: Provided is a compound represented by the following formula, or a salt thereof: [wherein each symbol is as defined herein.].

公开(公告)号：US10577382B2

公开(公告)日：2020-03-03

申请号：US16094030

申请日：2017-04-27

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Youichi Kawakita ,  Takuto Kojima ,  Noriyuki Nii ,  Yoshiteru Ito ,  Nobuki Sakauchi ,  Hiroshi Banno ,  Xin Liu ,  Koji Ono ,  Keisuke Imamura ,  Shinichi Imamura

IPC: C07D519/00 ,  A61K31/53 ,  A61P35/00

Abstract: Provided is a compound represented by the following formula, or a salt thereof: [wherein each symbol is as defined herein].

公开(公告)号：US10252997B2

公开(公告)日：2019-04-09

申请号：US15563128

申请日：2016-03-30

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Ryo Mizojiri ,  Moriteru Asano ,  Daisuke Tomita ,  Hiroshi Banno ,  Michiko Tawada ,  Noriyuki Nii ,  Krista E. Gipson ,  Hironobu Maezaki ,  Shuntarou Tsuchiya ,  Mayumi Imai ,  Yuichiro Amano

IPC: C07D213/65 ,  A61K31/165 ,  A61K31/167 ,  A61K31/277 ,  A61K31/381 ,  A61K31/402 ,  A61K31/415 ,  A61K31/42 ,  A61K31/421 ,  A61K31/426 ,  A61K31/427 ,  A61K31/44 ,  A61K31/4412 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/451 ,  A61K31/454 ,  A61K31/4965 ,  A61K31/50 ,  A61K31/501 ,  A61K31/505 ,  A61K31/506 ,  C07D213/75 ,  C07D213/81 ,  C07D231/12 ,  C07D333/20 ,  C07D401/04 ,  C07D237/14 ,  C07D239/34 ,  C07D409/04 ,  C07D413/04 ,  C07D241/18 ,  C07D417/04 ,  C07C233/18 ,  C07C233/47 ,  C07D261/08 ,  C07D263/32 ,  C07D263/42 ,  C07D207/08 ,  C07D207/12 ,  C07D277/34 ,  C07D211/44 ,  C07D213/643 ,  C07D213/69 ,  C07C233/25 ,  C07C255/54 ,  C07D211/46 ,  C07D213/74 ,  C07D401/12 ,  C12N9/99 ,  C12N15/09

Abstract: The present invention relates to a compound which may be useful as an agent for the prophylaxis or treatment of cancer, hepatitis, hepatic fibrosis, fatty liver and the like.

公开(公告)号：US20210332045A1

公开(公告)日：2021-10-28

申请号：US17367171

申请日：2021-07-02

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takaharu Hirayama ,  Yoshiteru Ito ,  Hiroshi Banno ,  Hidekazu Tokuhara ,  Toshio Tanaka ,  Yasuyoshi Arikawa ,  Noriyuki Nii ,  Youichi Kawakita ,  Shinichi Imamura

IPC: C07D471/04

Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.

公开(公告)号：US10696651B2

公开(公告)日：2020-06-30

申请号：US16323863

申请日：2017-08-09

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Jun Fujimoto ,  Xin Liu ,  Osamu Kurasawa ,  Terufumi Takagi ,  Douglas Robert Cary ,  Hiroshi Banno ,  Yasutomi Asano ,  Takuto Kojima

IPC: C07D401/12 ,  C07D403/12 ,  C07D401/14 ,  C07D213/75 ,  C07D405/12 ,  C07D239/42 ,  C07D241/12 ,  C07D471/04 ,  C07D498/04 ,  C07D213/65 ,  A61P35/00 ,  C07D241/20 ,  C07D213/73 ,  A61K31/53 ,  A61K31/505 ,  A61K31/4406 ,  A61K31/444 ,  A61K31/4965 ,  C07D213/68 ,  C07D213/42 ,  A61K31/506 ,  A61K31/497 ,  A61K31/4375 ,  C07D239/20 ,  A61P43/00 ,  A61K31/5383 ,  A61K31/437 ,  A61K31/44 ,  C07D253/06 ,  C07D231/12 ,  C07D239/30 ,  C07D239/34 ,  C07D239/48 ,  C07D253/07 ,  C07D409/12 ,  C07D487/04

Abstract: Provided is a heterocyclic compound that may have a GCN2 inhibitory action, and is expected to be useful for the prophylaxis or treatment of GCN2 associated diseases including cancer and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US09745325B2

公开(公告)日：2017-08-29

申请号：US15304727

申请日：2015-04-16

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masanori Okaniwa ,  Hiroshi Banno ,  Takaharu Hirayama ,  Douglas Robert Cary ,  Koji Ono ,  Naoki Iwamura

IPC: C07D513/04 ,  A61K31/429 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/455 ,  A61K31/5377

CPC classification number: C07D513/04 ,  A61K31/429 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/455 ,  A61K31/5377

Abstract: The present invention provides a fused heterocyclic compound that has CDK 8 and/or CDK 19 inhibitory activity. The present invention provides a compound represented by formula (I) (wherein the symbols are as defined in the description) or a salt thereof.